Clinical Report: Significant Metabolic Enhancement with Tirzepatide

Overview

This case study presents a 37-year-old woman with acquired partial lipodystrophy post-HSCT who experienced significant metabolic improvement after initiating tirzepatide therapy. The treatment led to enhanced glycemic control and improved hepatic steatosis.

Background

Acquired lipodystrophy is a rare condition often linked to severe insulin resistance and metabolic complications, particularly following hematopoietic stem cell transplantation (HSCT). The clinical features and treatment strategies for metabolic complications in these patients are not well defined. Tirzepatide, a dual agonist of GIP and GLP-1 receptors, has emerged as a novel therapeutic option for improving glycemic control in such cases.

Data Highlights

No numerical data available in the source material.

Key Findings

• A 37-year-old woman developed acquired partial lipodystrophy after HSCT, characterized by region-specific fat loss and severe insulin resistance.
• Glycemic control remained inadequate despite high-dose insulin therapy and treatment with GLP-1 receptor agonists.
• Initiation of tirzepatide resulted in dramatic improvement in glycemic control, allowing for complete discontinuation of insulin therapy.
• Body weight decreased modestly, and hepatic steatosis improved following tirzepatide treatment.
• The HMW/total adiponectin ratio increased after treatment, indicating potential improvement in adipocyte function.

Clinical Implications

This case illustrates the role of tirzepatide in managing metabolic disturbances associated with acquired lipodystrophy.

Conclusion

This case demonstrates a marked response to tirzepatide in acquired partial lipodystrophy.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Author(s)/Org, Source, Year -- Title
6. Author(s)/Org, Source, Year -- Title
7. Author(s)/Org, Source, Year -- Title
8. Full article: Clinical features of acquired lipodystrophy after total body irradiation: a case report and mini review
9. Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic
10. Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease | Eli Lilly and Company